First Light Asset Management LLC Lowers Stock Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

First Light Asset Management LLC trimmed its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 31.5% in the first quarter, Holdings Channel reports. The institutional investor owned 1,560,991 shares of the company’s stock after selling 717,949 shares during the period. Centessa Pharmaceuticals makes up 5.6% of First Light Asset Management LLC’s holdings, making the stock its 5th largest holding. First Light Asset Management LLC’s holdings in Centessa Pharmaceuticals were worth $62,003,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. Avoro Capital Advisors LLC grew its position in Centessa Pharmaceuticals by 34.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after buying an additional 3,747,475 shares in the last quarter. EcoR1 Capital LLC raised its holdings in Centessa Pharmaceuticals by 466.4% in the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after acquiring an additional 2,565,000 shares in the last quarter. Braidwell LP acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at $54,730,000. Maverick Capital Ltd. bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at $41,110,000. Finally, Adage Capital Partners GP L.L.C. lifted its position in shares of Centessa Pharmaceuticals by 20.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after acquiring an additional 1,449,000 shares during the period. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CNTA has been the topic of a number of recent analyst reports. Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target on the stock. in a research report on Monday, April 13th. Guggenheim cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Stephens lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $40.50 on Monday. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $12.74 and a 52-week high of $40.56. The business’s fifty day moving average is $40.14 and its 200-day moving average is $33.76. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The firm has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.